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NeurodegenerationTemporal lobe seizures lead to an acute inﬂammatory response in the brain primarily characterized by activation
of parenchymal microglial cells. Simultaneously, degeneration of pyramidal cells and interneurons is evident to-
gether with a seizure-induced increase in the production of new neurons within the dentate gyrus of the hippo-
campus.We have previously shown a negative correlation between the acute seizure-induced inﬂammation and
the survival of newborn hippocampal neurons. Here, we aimed to evaluate the role of the fractalkine–CX3CR1
pathway for these acute events. Fractalkine is a chemokine expressed byboth neurons and glia, while its receptor,
CX3CR1 is primarily expressed on microglia. Electrically-induced partial status epilepticus (SE) was induced in
adult rats through stereotaxically implanted electrodes in the hippocampus. Recombinant rat fractalkine or
CX3CR1 antibody was infused intraventricularly during one week post-SE. A signiﬁcant increase in the expres-
sion of CX3CR1, but not fractalkine, was observed in the dentate gyrus at one week. CX3CR1 antibody treatment
resulted in a reduction inmicroglial activation, neurodegeneration, as well as neuroblast production. In contrast,
fractalkine treatment had only minor effects. This study provides evidence for a role of the fractalkine–CX3CR1
signaling pathway in seizure-induced microglial activation and suggests that neuroblast production following
seizures may partly occur as a result of microglial activation.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Mesial temporal lobe epilepsy (MTLE), one of the most common
forms of focal epilepsies, is associated with a pathology in the hippo-
campus characterized by an acute inﬂammatory response and activated
parenchymal microglial cells, neurodegeneration, aberrant synaptic re-
organizations and an increase in adult neurogenesis (Bengzon et al.,
1997; Parent et al., 1997; De Simoni et al., 2000; Crespel et al., 2002;
Pitkanen and Sutula, 2002; Scharfman and Pedley, 2007; Ravizza et al.,
2008; Lu et al., 2009). A growing body of literature from both clinical
and experimental epilepsy research has during the last decade focused
in particular on how the inﬂammatory processes may contribute to
the development and severity of epilepsy (Vezzani et al., 2011).
Brain inﬂammation can affect both excitotoxicity-mediated neuro-
degeneration (Vezzani, 2005; Ulmann et al., 2013) as well as modulate
the seizure-induced neurogenesis (Jakubs et al., 2006; Ekdahl et al.,ell Therapy Group, Division of




. This is an open access article under2009). Acute microglial activation following epileptic seizures is detri-
mental to the survival of newly formed neurons (Ekdahl et al., 2003).
Both seizure-induced pathology and lipopolysaccharide-induced brain
inﬂammation alter the functional properties and the expression of syn-
aptic proteins, including adhesionmolecules and scaffolding proteins, of
adult born hippocampal neurons (Jakubs et al., 2006;Wood et al., 2011;
Jackson et al., 2012; Chugh et al., 2013). In addition, it has been speculat-
ed that microglia may regulate synaptic pruning and transmission in
adult born neurons (Ekdahl, 2012). Since newborn neurons are thought
to be involved inmemory formation during normal physiological condi-
tions (Jessberger et al., 2009; Deng et al., 2010), the additional number
of neurons born after seizures, may be an important restorative capacity
of the brain. The acute inﬂammatory response following seizures,which
compromises neurogenesis, may therefore be detrimental for brain re-
covery. The function of new neurons in a seizure-environment may,
however, be different from physiological conditions, though previous
observations from new seizure-induced neurons remaining within the
granule cell layer (GCL) of the dentate gyrus have suggested that they
may counteract hyperexcitability (Jakubs et al., 2006; Jackson et al.,
2012). Conversely, following more severe seizures, some new neurons
migrate aberrantly into the dentate hilus and there they may instead
propagate excitability (Parent et al., 1997; Scharfman et al., 2000;the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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mation for these aberrant neurons remains unclear.
One way to further understand how inﬂammation and other
seizure-induced brain pathologies are related is to study single potential
signaling pathways betweenmicroglia and neurons. Various inﬂamma-
tory mediators which are known to regulate microglial activation
(Cardona et al., 2006; D'Haese et al., 2012), have also been implicated
in adult neurogenesis and synaptic transmission (Butovsky et al.,
2006; Lauro et al., 2010; Scianni et al., 2013). Fractalkine is an inﬂamma-
tory chemokine secreted by neurons and astrocytes. It acts on G-protein
coupled CX3CR1 receptors, present primarily on microglial cells, and
regulates its activation, migration and phagocytic activity (Harrison
et al., 1998; Fuhrmann et al., 2010; Noda et al., 2011). In addition, the
fractalkine–CX3CR1 signaling pathway has also been implicated in
tuning neurogenesis and synaptic transmission (Bachstetter et al.,
2011; Paolicelli et al., 2011). Furthermore, recent studies have depicted
a role of the fractalkine–CX3CR1 pathway in the pathogenesis of epilep-
sy and associated cell death (Yeo et al., 2011; Xu et al., 2012). An
increased expression of fractalkine and CX3CR1 receptors is reported
in the surgically resected brain samples from MTLE patients and in ex-
perimental animal models of MTLE (Xu et al., 2012; Roseti et al., 2013).
In the present study, we aimed to investigate the role of the
fractalkine–CX3CR1 signaling pathway for acute seizure-induced
microglial activation, neurodegeneration, and neuroblast production
following partial status epilepticus (SE). To achieve this, we performed
continuous intraventricular infusion of anti-CX3CR1 antibody or recom-
binant fractalkine for seven days immediately following electrically-
induced SE in the temporal lobe of adult rats.
Materials and methods
Animals
Adult male Sprague–Dawley rats (n = 77) weighing between 200
and 250 g were procured from Charles River (Germany). Rats with
generalized-status epilepticus semiology, absence of sustained
seizures after electrical stimulations, incorrect electrode placements
or hydrocephalous due to hippocampal injury were excluded from the
study. After exclusions, 33 animals served as non-stimulated or SE-
vehicle treated controls, whereas 28 animals were used for either of
the treatment groups (SE-CX3CR1 and SE-fractalkine) included in this
study. The animals were either used for immunohistochemical analysis
or ELISA/Western blots studies. The number of animals used for each as-
sessment is described in theﬁgure legends aswell as in the relevant text
in the Results section. Additionally, we used CX3CR1GFP/+ heterozygous
mice (n= 4), 2 non-stimulated controls and 2 SE mice (originally bred
by Dr. Steffen Jung, Rehovot, Israel, and kindly provided by Dr. William
Agace, Lund, Sweden). The animals were housed in a 12 h light/dark
cycle with ad libitum food and water. All experimental procedures
were performed in accordance with the guidelines set by the Malmö-
Lund Ethical Committee for the use and care of laboratory animals.
Surgery and induction of status epilepticus (SE)
Animals were anesthetized with 2% isoﬂurane and implanted with a
bipolar insulated stainless steel electrode (Plastics One, Roanoke, VA)
into the right ventral CA1/CA3 region of the hippocampus (coordinates:
4.8 mm posterior and 5.2 mm lateral from bregma; and 6.3 mm ventral
from dura, toothbar set at−3.3 mm) (Paxinos and Watson, 1998) for
stimulation and recording. Another electrode (unipolar) was placed
between the skull and adjacent muscle to serve as ground electrode.
Additionally, a brain infusion cannula (Brain Infusion Kit 1, Alzet) was
implanted in the lateral ventricle (coordinates: 1.0 mm posterior and
1.5 mm lateral to bregma; and 3.5 mm ventral to the ﬂat skull position
with bregma as reference) in the ipsilateral hemisphere. Following
a week of recovery, rats were subjected to electrically-induced SEaccording to the protocol described in Jackson et al. (2012). Electrode-
implanted rats with no stimulations served as controls for the SE rats.
Initially, afterdischarge thresholds were determined for each rat by
applying a square wave biphasic pulse (50 Hz) of 1 s train duration at
a starting intensity of 10 μA, then increasing by 10 μA every 1 min
until a 10 s afterdischarge was evoked. For inducing SE, suprathreshold
stimulation was applied for 1 h, with interruptions in the stimulation
every 9th minute to record electroencephalographic (EEG) activity for
1 min. Subsequently, the ictal EEG activity was recorded for another
2 h and the behavioral seizures were classiﬁed according to Racine's
(1972) scale. Only rats that displayed self-sustained ictal EEG activity
for 2 h in the temporal lobe as well as a partial seizure semiology
were included in this study. The ictal EEG activity was then completely
interrupted by administering pentobarbital (65 mg/kg, intraperitoneal
injection). CX3CR1GFP/+ heterozygous mice underwent electrode im-
plantation surgery (coordinates: 2.9 mm posterior and 3.0 mm lateral
from bregma; and 3.0 mm ventral from dura) (Franklin and Paxinos,
1997) and SE induction, similar to the protocol described for rats.
Intracerebroventricular drug infusion
Once rats were anesthetized following SE, the brain infusion cannula
was connected with osmotic pumps (1007D, Alzet) carrying either of
the following drugs: rabbit anti-CX3CR1 antibody (20 μg/ml (low dose)
or 60 μg/ml (high dose) (Abcam, UK)), recombinant rat fractalkine
(2 μg/ml, R&D Systems, USA) or vehicle (phosphate buffer saline).
Infusion rate was 0.5 μl/h. Non-stimulated rats were also connected
with osmotic pumps carrying vehicle to serve as controls. The osmotic
pumps were placed in the subcutaneous pocket in the dorsal region of
the neck.
Tissue processing
Seven days after SE induction, rats and mice were either used for
immunohistochemical studies or ELISA/Western blots. An additional
cohort of rats was sacriﬁced at 6 h after the induction of SE to assess
the levels of inﬂammatory cytokines using ELISA. For immunohisto-
chemistry, rats and mice were trans-cardially perfused with 0.9% saline
and 4% paraformaldehyde. The brains were collected and post-ﬁxed in
paraformaldehyde overnight, afterwhich theywere kept in 20% sucrose
solution at 4 °C until sectioning. The brains were cut in 30 μm sections
on a freezing microtome. The sections were collected in a glycerol
based anti-freeze solution distributed into ten series, and stored in
−20 °C until used for immunohistochemistry. The cohort of rats for
ELISA and Western blot analysis was transcardially perfused with 0.9%
saline. The brains were collected, and contralateral hippocampal tissues
were extracted and immediately frozen in dry ice. The tissueswere then
stored in−80 °C until protein isolation.
Immunohistochemistry
For immunohistochemistry, the following primary antibodies were
used: rabbit anti-Iba1 (1:1000, Wako, Japan), mouse anti-CD68/ED1
(1:200, AbD Serotec, Germany), goat anti-doublecortin (DCX) (1:200,
Santa Cruz Biotechnology, Germany), rabbit anti-Ki67 (1:400, Leica
Biosystems, Novocastra, Sweden), rabbit anti-CX3CR1 (1:100, Abcam,
UK), mouse anti-NeuN (1:100, Millipore, Bioscience Research Reagents,
CA, USA), rabbit anti-fractalkine (1:200, Abcam), and mouse anti-glial
ﬁbrillary acidic protein (GFAP) (Sigma, Germany). For all stainings
(except for Iba1 and ED1), free-ﬂoating sections were subjected to an
initial antigen retrieval stepwith incubation of sections in sodiumcitrate
buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6). Subsequently,
sections were incubated with an appropriate primary antibody over-
night at 4 °C in blocking serum, except during CX3CR1 staining when
sectionswere incubated in primary antibody overnight at room temper-
ature. This was followed by 2 h of incubation in secondary antibody at
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brain sections went through the entire protocol without primary
antibody incubation, to serve as the negative controls. The following sec-
ondary antibodies were used: Cy3-conjugated donkey anti-mouse/
rabbit (Jackson Immunoresearch, UK), biotinylated goat anti-rabbit
(1:200, Vector Laboratories, UK), biotinylated horse anti-goat (1:200,
Vector Laboratories), or Alexa-488 conjugated streptavidin (1:200,
Invitrogen, Sweden). The sections were mounted on gelatin-coated
slides and coverslipped using a glycerol-based mounting medium
(DABCO, Sigma).ELISA
Protein samples from contralateral hippocampi were isolated as
described before (Chugh et al., 2013). Total protein concentration was
determined by BCA protein assay (BCA, Pierce, Rockford, USA) as per
the manufacturer's instructions. Interleukin-1β (IL-1β), IL-6, IL-4, and
IL-10 concentrationswere determined by ELISA (Duoset, R &D Systems,
MN, USA) according to the manufacturer's protocol. Brieﬂy, 50–100 μg
of a protein sample was loaded per well and incubated on a shaker for
2 h at room temperature. For each assay, samples were analyzed in du-
plicates, and were compared with protein standards. Plates were read
on a Perkin Elmer Victor™ Xmultilabel plate reader. For the assessment
of inﬂammatory mediators at 6 h after SE, cytokine levels were mea-
sured in hippocampal supernatants by sandwich immunoassay
methods using a commercially available electrochemiluminescent
detection system, and commercially available plates and reagents
(V-PLex Pro-inﬂammmatory Panel 1 (rat) kit, Meso-scale Discovery
(MSD), Gaithersburg, Maryland) as per themanufacturer's instructions
withminor modiﬁcations. Brieﬂy, 50 μl of the protein sample was load-
ed per well of theMSD plate (~100 μg of protein). The samples were in-
cubated overnight at 4 °C with shaking. For each assay, samples were
analyzed in duplicates, and compared with known concentrations of
protein standard. Plates were analyzed using the SECTOR Imager 2400.Western blot analysis
Protein samples were denatured at 99 °C for 5 min in 2× Laemmli
sample buffer (Bio-Rad, Germany). Total protein (10 μg) was resolved
on precast 4–15% mini-PROTEAN® TGX™ (Bio-Rad) sodium dodecyl
sulfate polyacrylamide gels and transferred using Trans-Blot® Turbo™
mini nitrocellulose transfer packs (Bio-Rad). The membranes were
blocked for 2 h at room temperature in Tris-buffered saline (pH 7.4)
with 0.2% (w/v) Tween 20 (TBS-T) containing 5% nonfat dried milk for
β-actin, gephyrin and post-synaptic density (PSD)-95 and with 3% bo-
vine serum albumin (BSA, Sigma) for IL-1 receptor-1 (IL-1R1) and
tumor necrosis factor receptor 2 (TNFR2). Membranes were then incu-
bated for overnight at 4 °C with primary antibodies diluted in TBS-T
containing 0.5% BSA. The following primary antibodies were used:
mouse monoclonal anti-β actin (1:10,000, Sigma), mouse monoclonal
anti-gephyrin (1:3000, Synaptic Systems, Germany), mouse mono-
clonal anti-PSD-95 (1:200, Abcam), rabbit polyclonal anti-TNFR2
(1:250, Santa Cruz Biotechnology), and rabbit polyclonal anti-IL-
1R1 (1:500, Santa Cruz Biotechnology). After washing off the prima-
ry antibody, membranes were incubated with secondary antibody
diluted in 0.5% BSA for 2 h at room temperature. Secondary antibod-
ies were either horseradish peroxidase-conjugated anti-mouse
(1:5000, Sigma), or anti-rabbit (1:5000, Sigma) diluted in TBS-T
containing 0.5% BSA. The membranes were then washed again for
three times in TBS-T. Immunoreactive bands were visualized by en-
hanced chemiluminescence (Bio-Rad), and images were acquired
using the Chemidoc™ XRS+ system (Bio-Rad). Band intensities were
quantiﬁed using ImageJ software (NIH, USA) and β-actin was used as
a loading control.Fluoro-Jade staining
Free-ﬂoating sections were washed with potassium phosphate
buffer saline mounted on gelatin-coated slides, and dried overnight.
The sections were then hydrated, pretreated with 0.06% potassium per-
manganate for 15 min, rinsed with distilled water and treated with
0.001% Fluoro-Jade (Histo-Chem, Jefferson, AR, USA) for 30min,washed
with distilled water, dehydrated by treatment with ethanol and xylene,
and then coverslipped with Pertex mounting medium.
Cell counts and image analyses
All quantiﬁcations were performed in 3–4 sections (from−3.3 mm
to−4.6 mm posterior to bregma) from brain hemisphere contralateral
to the stimulated region by an experimenter blind to the treatment con-
ditions as previously described in Jakubs et al. (2006). The Iba1/ED1,
DCX and Fluoro-Jade+ cell counts were performed using an Olympus
BX61 epiﬂuorescence microscope in the hippocampal GCL, dentate
hilus and molecular layer (ML), while Ki67+ cells were additionally
counted in the subgranular zone (SGZ), the zone comprising the inner-
most row of cells in the GCL along with two cell diameter thick regions
at the GCL/hilar border. The data is expressed as mean number of cells/
section, based on average number of cells in 3–4 sections. Moreover, a
total of 100 Iba1+ cells were analyzed for all of the three microglial
morphological subtypes including ramiﬁed, intermediate and round/
amoeboid in each region of interest. The relative occurrence of each
morphological subtype is expressed as the percentage of the ﬁxed num-
ber of microglial Iba1 counts (100 cells/rat) for each region of interest.
For estimating the co-labeling of GFP+ with Iba1+, GFAP+ and
NeuN+ cells, respectively, 50–60 cells were analyzed per section from
a total of 4 sections per mouse in the GCL/SGZ, ML, and dentate hilar re-
gion in the naïve and SE-induced CX3CR1GFP/+ heterozygous mice.
For CX3CR1 expression, four representative images were taken at a
20× objective (from −3.3 to −4.6 mm posterior to bregma) with a
BX61 epiﬂuorescence microscope and the ﬂuorescent intensity on the
microglial cells were qualitatively graded from 1 to 5, with 1 being the
lowest intensity and 5 being the highest. The values were then
expressed as median ± range for each experimental group.
To quantify fractalkine and GFAP expression, four representative
images from the hippocampal GCL and dentate hilus (from −3.3 to
−4.6 mm posterior to bregma) were acquired using a BX61
epiﬂuorescence microscope with 20× objective. The images were then
analyzed as described previously in Chugh et al. (2013) using the ImageJ
software. The ﬂuorescence intensities are reported after subtracting the
intensity measurements from that of negative control samples.
Statistical analyses
Statistical analyses (Graphpad Prism software) were performed using
the unpaired Student's t-test when comparing 2 groups. Statistical analy-
ses for CX3CR1 expressionwas performed using theMann–Whitney test.
Microglial morphology proﬁle data was analyzed by using two-way
ANOVA. All data are expressed as mean ± SEM, except for CX3CR1 ex-
pression,which is expressed asmedian±range. Differenceswere consid-
ered statistically signiﬁcant at p ≤ 0.05.
Results
Acute pathophysiological changes in the dentate gyrus of the hippocampus
one week after status epilepticus
At oneweek following SE,we observed profoundmicroglial activation
in the hippocampuswith increasedmicroglial cell numbers as well as the
presence of activated microglial phenotypes. The number of Iba1+ cells
was increased in the GCL and dentate hilus, but not in the ML in
vehicle-treated SE (SE) compared to vehicle-treated non-stimulated
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quantiﬁed as the percentage of Iba1+ cells expressing ED1, were in-
creased in the GCL, ML, and dentate hilus (Fig. 1B). In addition, we
assessed the morphological phenotypes of microglia; ramiﬁed/surveying
(Fig. 1C), intermediate (Fig. 1D) and round/ameboid (Fig. 1E)
morphology. In SE rats, the percentage of surveying/ramiﬁed microglia
was decreased by about 85% along with an increased intermediate and
round morphology, which suggests a more activated phenotype, in the
GCL (Fig. 1F), ML (Fig. 1G) and dentate hilus (Fig. 1H).
However, despite a strong increase in the microglial activation one
week following SE induction, we could not detect any changes in
the protein expression levels of pro-inﬂammatory cytokines in the hip-
pocampus including IL-1β (373.4 ± 53.06 pg/mg in NSC vs 365.8 ±
15.48 pg/mg in SE rats; n = 5 for each group) and IL-6 (233.4 ± 54.29
pg/mgNSC vs 255.9± 85.83 pg/mg SE), or anti-inﬂammatory cytokinesFig. 1. Status epilepticus (SE)-induced increase in microglial activation, neuronal degeneration
ﬁcation of Iba1+ (A) and percentage of Iba1+ED1+ cells (B) in the granule cell layer (GCL),mole
(NSC) and SE. C–E, Representative photomicrographs of different microglial morphological ph
E) Iba1+ cells. F–H, Quantiﬁcation of relative percentage of microglia with different morphol
Jade+ (FJ+) cells (arrow heads) in NSC (I) and SE (J). K, Quantiﬁcation of FJ+ cells in the GCL,
heads) in NSC (L) and SE (M). N–O, Quantitation of DCX+ cells in the GCL/sub-granule zone (
and n = 4 SE group. *, p ≤ 0.05 un-paired t-test compared to controls in A, B, K, N and O and tincluding IL-4 (18.93 ± 3.30 pg/mg NSC vs 16.66± 2.24 pg/mg SE) and
IL-10 (12.08± 1.01 pg/mgNSC vs 16.18± 3.31 pg/mg SE). Similarly, no
changes were detected with Western blots in mean protein levels of
two cytokine receptors; IL-1R1 (100.0 ± 3.02% NSC vs 94.8 ± 11.31%
SE; n = 5 for each group) or TNF R2 (100.0 ± 17.29% NSC vs 124.5 ±
21.79% SE) normalized to the expression of β-actin, at this time point.
However, we did ﬁnd a signiﬁcant acute increase in the expression of
IL-6 in the hippocampus 6 h after SE compared to non-stimulated con-
trol rats (Supplementary Fig. 1).
There was a moderate increase in ongoing cell death within the
hippocampus (Figs. 1I and J) in terms of the increased number of
Fluoro-Jade+ cells in the GCL and dentate hilus of SE compared to NSC
rats (Fig. 1K).
In order to detect a possible imbalance in synaptic excitation and in-
hibition one week post-SE, we quantiﬁed the hippocampal proteinand neuroblast production in the dentate gyrus of the hippocampus in adult rats. Quanti-
cular layer (ML) and hilus of the dentate gyrus in vehicle-treated, non-stimulated controls
enotypes including ramiﬁed (Ram, C), intermediate (Inter, D) and round/ameboid (R/A,
ogies in the GCL (F), ML (G) and dentate hilus (H). I–J, Representative images of Fluoro-
ML and dentate hilus. L–M, Representative images of doublecortin+ (DCX+) cells (arrow
SGZ) (N) and Ki67+ cells in the SGZ of the dentate gyrus (O). Means ± SEM, n = 5 NSC
wo-way ANOVA in F–H. Scale bars are 5 μm for C–E and 40 μm in I–M.
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inhibitory and excitatory synapses, respectively. However, we did not
detect any signiﬁcant changes (gephyrin; 100.0 ± 6.7% NSC vs
109.3 ± 7.9% SE, PSD-95; 100.0 ± 9.9% NSC vs 117.7 ± 32.5% SE,
normalized to the expression of β-actin and presented as percentage
change in expression relative to non-stimulated controls).
Neuroblast production, estimated by the number of DCX+ cells in
the GCL/SGZ of the dentate gyrus (Figs. 1L and M), was increased in SE
compared to NSC, thus corroborating previous ﬁndings (Fig. 1N). Also,
the number of Ki67+ cells in the SGZ was increased, which reﬂects the
extent of cell proliferation (Fig. 1O).Fractalkine and CX3CR1 expression in the dentate gyrus of the hippocampus
one week after status epilepticus
We did not detect a change in the expression of fractalkine in the
GCL (mean intensities: SE 28.88 ± 1.97; n = 8 vs NSC 31.50 ± 3.28;
n = 7) or the dentate hilus (SE 23.45 ± 1.56 vs NSC 30.48 ± 3.22) of
SE compared to NSC rats (Figs. 2A–B). However, there was a signiﬁcant
increase in the CX3CR1 expression in the dentate gyrus of SE rats, when
compared to NSC rats (Figs. 2C–D) (median of 4 with a range between
3.75 and 5 in intensity scores for SE; n = 4 vs median of 1 with a
range of 0.25 to 1.25 for NSC; n = 5).
In order to assess the microglial speciﬁcity of CX3CR1, we used
CX3CR1GFP/+ heterozygous mice to conﬁrm a 100% overlap between
CX3CR1 expression and Iba1+ cells in control mice as well as one
week after electrically-induced SE (Figs. 2E–F). No overlap was ob-
served with the astrocytic and neural progenitor marker GFAP
(Figs. 2G–H) or the neuronal marker NeuN (Figs. 2I–J).Effect of fractalkine infusion on status epilepticus-induced pathology
Wenext explored ifmodulating the fractalkine–CX3CR1 pathway by
fractalkine infusion affects hippocampal pathology one week after SE.
First, we assessed the microglial cell numbers and activation proﬁles
in the vehicle-treated SE versus fractalkine-treated SE rats (Figs. 3A–F).
Fractalkine infusion following SE, did not affect Iba1+ cell counts in
the GCL, ML or dentate hilus of the hippocampus (Fig. 3A). Similarly,
no changeswere detected in the percentage of Iba1+microglial cells ex-
pressing ED1 (Fig. 3B). In addition, there were no alterations in the
number of proliferating Ki67+ cells (Fig. 3C) or microglial morphologi-
cal phenotypes in the GCL, ML or dentate hilus (Figs. 3D–F).Fig. 2. Expression of fractalkine and CX3CR1 in the dentate gyrus one week after SE. A–D, Repr
expression (arrowheads) inNSC (C) and SE (D). E–F, Representative orthogonal projectionswit
GFP/+mice, NSC (E) and SE (F). G–H, Images of GFAP+ cells (red) not co-localizedwith GFP+ cell
localized with GFP+ cells (green) in CX3CR1GFP/+ mice, NSC (I) and SE (J). Scale bar is 40 μm iConsistent with the immunohistochemical ﬁndings, we did not de-
tect any changes in the protein expression levels of IL-1β (365.8 ±
15.48 pg/mg SE-Veh, n = 5 vs 328.8 ± 22.34 pg/mg SE-fractalkine,
n = 4), IL-6 (255.9 ± 85.83 pg/mg SE-Veh vs 66.9 ± 26.67 pg/mg
SE-fractalkine), IL-4 (16.66 ± 2.24 pg/mg SE-Veh vs 11.83 ± 2.3
pg/mg SE-fractalkine), or IL-10 (16.18 ± 3.31 pg/mg SE-Veh vs
12.3 ± 2.58 pg/mg SE-fractalkine) in the hippocampus. Similarly, no
changes were detected in mean protein levels of IL-1R1 (94.8 ± 11.31%
SE-Veh vs 101.9 ± 9.4% SE-fractalkine) or TNF R2 (124.5 ± 21.79% SE-
Veh vs 92.8 ± 16.7% SE-fractalkine normalized to the expression of
β-actin and presented as percentage change in expression relative
to non-stimulated controls rats). In addition, we observed no changes
in the protein expression of gephyrin (109.3 ± 7.9% SE-Veh vs
112.0 ± 14.4% SE-fractalkine) or PSD-95 (117.7 ± 32.5 SE-Veh vs
142.6 ± 23.7% SE-fractalkine) in the hippocampus.
Furthermore, fractalkine treatment did not affect the numbers of
Fluoro-Jade+ cells in GCL, ML, or dentate hilus (Fig. 3G) or DCX+ cells
in theGCL/SGZ (Fig. 3H). However, it did lead to an increase in the num-
bers of Ki67+ cells in the SGZ (Figs. 3I–K).CX3CR1 antibody infusion decreases status epilepticus-induced microglial
activation
We evaluated the infusion of two different doses of CX3CR1 anti-
body based on Yeo et al. (2011). The lower dose of CX3CR1 antibody in-
fusion during one week post-SE led to a signiﬁcant reduction in the
number of Iba1+ cells in the GCL of the hippocampus as well as a re-
duced percentage of Iba1+ cells expressing ED1 in the GCL,ML and den-
tate hilus compared to the vehicle-treated SE group (Figs. 4A–D). Also,
the number of Ki67+ cells was signiﬁcantly reduced in the dentate
hilus, while no differences were detected in the GCL or ML (Fig. 4E).
Moreover, when comparing the morphological proﬁles for different
microglial activation states, we observed a signiﬁcant interaction be-
tween the microglial morphology and treatment groups in the GCL
(Fig. 4F) and ML (Fig. 4G), which was primarily due to an increase in
the percentage of microglial cells with ramiﬁed morphology in the
CX3CR1 antibody-treated rats. However, microglial morphology was
not affected in the dentate hilus (Fig. 4H). The change in microglial
activation proﬁle induced by CX3CR1 antibody treatment was not ac-
companied by a change in the protein expression levels of IL-1β
(365.8 ± 15.48 pg/mg SE-Veh vs 354.8 ± 22.43 pg/mg SE-CX3CR1;
n = 5 in each group), IL-6 (255.9 ± 85.83 pg/mg SE-Veh vs 133.0 ±
42.17 pg/mg SE-CX3CR1), IL-4 (16.66 ± 2.24 pg/mg SE-Veh vsesentative photomicrographs of fractalkine expression in NSC (A) and SE (B) and CX3CR1
h confocal microscopy of Iba1+ cells (red) co-localizedwith GFP+ cells (green) in CX3CR1-
s (green) in CX3CR1GFP/+mice, NSC (G) and SE (H). I–J, Images of NeuN+ cells (red) not co-
n A for A–D and 10 μm in E for E–J.
Fig. 3. Effect of fractalkine treatment on SE-induced pathology. Quantiﬁcation of the number of Iba1+ (A), percentage of Iba1+ED1+ cells (B), and Ki67+ (C) cells, relative percentage of
microglial morphologies in the GCL (D), ML (E) and dentate hilus (F), and FJ+ (G), and DCX+ cells (H) of vehicle-treated SE (SE-Veh) and fractalkine-treated SE rats (SE-fractalkine). I–J,
Representative images of Ki67+ cells (arrow heads) in the dentate gyrus of the SE-Veh (I) and SE-fractalkine groups (J). K, Quantiﬁcation of Ki67+ cells in the SGZ of the dentate gyrus of
the SE-Veh and SE-fractalkine groups. Means± SEM, n=8 and 7 for SE-Veh and SE-fractalkine respectively for A–F and K and n=4 in each group for G andH. *, p≤ 0.05 un-paired t-test
compared to controls in A–C & G–K and two-way ANOVA in D–E. Scale bar is 40 μm.
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vs 14.68 ± 0.72 pg/mg SE-CX3CR1) at one week post-SE. Similarly, no
changes were detected in mean protein levels of IL-1R1 (94.8 ±
11.31% SE-Veh vs 97.4 ± 8.5% SE-CX3CR1) or TNF R2 (124.5 ± 21.79%
SE-Veh vs 110.2 ± 13.84% SE-CX3CR1).
In contrast to changes in microglial activation, the lower dose of the
CX3CR1 antibody treatment did not induce changes in ﬂuorescent in-
tensity of the astrocytic marker GFAP in the GCL, ML or the dentate
hilus of the hippocampus (Fig. 4I).
The higher dose of CX3CR1 antibody did not reduce microglial acti-
vation and numbers, or altered their morphologies in the dentate
gyrus after SE (n = 4 in each group; data not shown). In fact, we even
observed a trend towards an increase in the number of Iba1+ cells
(p = 0.07) in the dentate hilus (data not shown). Since there were
no signiﬁcant changes, we opted to use the lower dose for further
evaluations.
CX3CR1 antibody infusion decreases status epilepticus-induced neuronal
degeneration
The CX3CR1 antibody infusion reduced the number of Fluoro-Jade+
cells in the dentate hilus of the hippocampus one week post-SE
(Figs. 5A–C), suggesting a neuro-protective effect in the sub-region of
the dentate gyrus with the highest extent of SE-induced cell death. No
differences were seen in the GCL or ML (Fig. 5C).
In terms of imbalance in excitatory/inhibitory scaffolding proteins, the
CX3CR1 infusion did not alter the expression of gephyrin (109.3 ± 7.9%SE-Veh vs 108.6 ± 1.4% SE-CX3CR1) or PSD-95 (117.7 ± 32.5 SE-Veh vs
110.8 ± 6.96% SE-CX3CR1) in the hippocampus.
CX3CR1 antibody infusion decreases status epilepticus-induced neuroblast
production
Finally, we quantiﬁed the initial stages of seizure-induced neuro-
genesis within the hippocampus by measuring neuroblast production
one week following SE. We found a 38% reduction in the number of
DCX+ cells in the GCL/SGZ of CX3CR1 antibody-treated SE as compared
to vehicle-treated SE rats (Figs. 6A–C). The decrease in DCX+ cells was
further supported by a 53% decrease in the number of proliferating
Ki67+ cells within the SGZ of the dentate gyrus (Figs. 6D–F).
Discussion
In the current study, we describe a role of the fractalkine–CX3CR1
pathway for the acute pathological changes in the brain following
an epileptic insult. Blocking this pathway by administering the
anti-CX3CR1 antibody diminished electrical SE-induced microglial
activation, neurodegeneration and neuroblast formation in the adult
rat hippocampus.
We observed an increased expression of CX3CR1 in the hippocam-
pus one week following SE. Increased expression of fractalkine and
CX3CR1 has been reported in resected hippocampal sections from epi-
leptic patients as well as in the animal model of MTLE (Yeo et al.,
2011; Xu et al., 2012; Roseti et al., 2013). An increased level of
Fig. 4. CX3CR1 antibody treatment decreasesmicroglial activation oneweek after SE. A–B, Representative images of Iba1+ (green) and Iba1+/ED1+ (yellow) cells in vehicle-treated SE (SE-Veh)
(A) and CX3CR1 antibody-treated SE rats (SE-CX3CR1) (B). Quantiﬁcation of the number of Iba1+ (C), and percentage of Iba1+ ED1+ cells (D), Ki67+ cells (E), and relative percentage of
microglial morphologies in the GCL (F), ML (G), and dentate hilus (H). I, Densitometric analysis of GFAP expression in the GCL, ML, and dentate hilus of the SE-Veh and SE-CX3CR1 groups.
Means ± SEM, n = 8 in each group for A–H and n= 4 in each group for I. *, p ≤ 0.05 un-paired t-test compared to controls in C–E & I and two-way ANOVA in F–H. Scale bar is 40 μm.
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leptic patients (Xu et al., 2012). However, we could not detect an in-
crease in the fractalkine expression one week post-SE in our animal
model. This ﬁnding is in line with a previous study (Yeo et al., 2011),
which even reported a reduced fractalkine expression at 3 days after
SE, despite showing an increase at earlier time points. We found no ev-
idence for the presence of CX3CR1 in cells expressing the astrocytic and
neural progenitor cell marker GFAP (Jessberger et al., 2005) or theFig. 5. CX3CR1 antibody treatment decreases neuronal degeneration one week after SE. A–B, R
gyrus of the SE-Veh (A) and SE-CX3CR1 groups (B). C, Quantiﬁcation of FJ+ cells. Means± SEMmature neuronal marker NeuN, but 100% co-localization was observed
with the microglial cell marker Iba1, in the dentate gyrus of both
naïve and SE-induced CX3CR1GFP/+ heterozygous mice. This suggests
that modulation of the CX3CR1 pathway primarily affects the microglia
population.
Administration of the anti-CX3CR1 antibody reduced SE-induced
microglial activation, in terms of increased numbers of ramiﬁed/
surveying microglia together with a reduced percentage of microglialepresentative photomicrographs of Fluoro-jade+ (FJ+) cells (arrow heads) in the dentate
, n = 4 in each group. *, p≤ 0.05 un-paired t-test compared to controls. Scale bar is 40 μm.
Fig. 6. CX3CR1 antibody treatment decreases neuroblast production oneweek after SE. A–B, Representative images of DCX+ cells (green) in the SE-Veh (A) and SE-CX3CR1 groups (B). C,
Quantiﬁcation of DCX+ cells (C). D–E, Representative images of Ki67+ cells (red) in the SE-veh (D) and SE-CX3CR1 groups (E). F, Quantiﬁcation of Ki67+ cells. Means± SEM, n=4 in each
group. *, p ≤ 0.05 un-paired t-test compared to controls. Scale bar is 40 μm.
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gyrus. This decrease is in line with the ﬁndings of Yeo et al. (2011),
where they showed reduced microglial numbers in the hippocampus,
3 days after pilocarpine-induced SE in rats treated with the same low
dose (20 μg/ml) of anti-CX3CR1 antibody used in this study, from
4 days pre- and 3 days post-SE. Conversely, in an attempt to further
activate the pathway, we administered recombinant fractalkine.
However, the present treatment protocol did not change microglial
numbers, morphology, or ED1 expression in the dentate gyrus, possibly
due to the high percentage of already activated microglia in the SE-
vehicle rats.
Ablation of CX3CR1 receptors in mice leads to reduced microglial
numbers during the ﬁrst month of age during normal physiological
condition (Paolicelli et al., 2011). However, blocking CX3CR1 signaling
in the physiological environment with administration of an antibody
(10 μg/day) has also been shown to enhance microglial numbers
(Bachstetter et al., 2011). Similarly, in other brain pathological condi-
tions, such as neurodegenerative disorders, ischemic brain injury or spi-
nal nerve injury, modulating this pathway has given discordant
outcomes with respect to microglial activation (Lee et al., 2010;
Sheridan and Murphy, 2013; Wu et al., 2013; Tang et al., 2014). The
mixed reports including both increased and decreased activation of mi-
croglia in response to inhibition of the fractalkine–CX3CR1 pathway in a
pathological brain environment has already been suggested to depend
on the severity and chronicity of the insult (Cardona et al., 2006). It
has also been suggested that during physiological conditions, tonic acti-
vation of CX3CR1 by fractalkine helps to keep the microglia in a quies-
cent state. However, during an inﬂammatory condition, levels of
fractalkine/CX3CR1 expression may increase and promote microglial
migration and activation to the site of inﬂammation (Rogers et al.,
2011; Sheridan and Murphy, 2013). Hence, another possibility for the
discrepancy among different reports could be differences in the degree
of inhibition, timing of treatment and dose–responses of treatment. Our
results may support this argument since the low dose CX3CR1 antibodytreatment reduced microglial activation, while we observed a trend
towards an increase in microglial activation with the higher dose
(60 μg/ml).
Despite a pronounced SE-induced increase in microglial numbers
and morphological alterations, we did not observe a change in the hip-
pocampal expression of some pro- and anti-inﬂammatory cytokines at
one week post-SE, with or without the CX3CR1 antibody treatment.
The initial increase in IL-6, within hours after SE, was only transient.
This does not exclude alterations in cell-type or sub-regional speciﬁc ex-
pression within the hippocampus at any of the investigated time points
after the insult (De Simoni et al., 2000; Ravizza et al., 2008). However,
our data suggests that there is no prominent continuous cytokine re-
lease at one week post-SE.
The anti-CX3CR1 antibody treatment diminished the SE-induced
neurodegeneration in the dentate hilus. In agreement, the fractalkine–
CX3CR1 pathway has been shown to regulate bothmicroglial activation
and microglia-induced neurotoxicity by modulating microglial mobili-
zation, their binding to dying neurons and release of cytokines
(Harrison et al., 1998; Fuhrmann et al., 2010; Fumagalli et al., 2013;
Sheridan and Murphy, 2013; Brown and Neher, 2014). Accordingly,
we observed a reduced percentage of activated microglial cells in
the dentate hilus of CX3CR1 antibody-infused rats. This, along with an
overall increased population of ramiﬁed and less intermediate forms
of microglia in the dentate gyrus could mitigate the SE-induced
excitotoxicity and cell death (Li et al., 2012). However, previous reports
are rather complex and suggest even a protective effect of the
fractalkine–CX3CR1 pathway in microglia/neuronal cell cultures in re-
sponse to LPS and glutamate-mediated neurotoxicity (Zujovic et al.,
2000; Deiva et al., 2004; Limatola et al., 2005). In an attempt to further
evaluate the neuroprotective effect of inhibiting the CX3CR1 pathway,
we studied the expression of excitatory and inhibitory synaptic scaffold-
ing proteins, PSD-95 and gephyrin, which may suggest an imbalance in
neuronal excitability as a contributor to neurodegeneration. PSD-95 and
gephyrin are known to modulate excitatory and inhibitory synaptic
202 I. Ali et al. / Neurobiology of Disease 74 (2015) 194–203transmission (Beique and Andrade, 2003; Prange et al., 2004; Varley
et al., 2011) and the fractalkine–CX3CR1 pathway has been shown to
regulate both glutamatergic excitatory andGABAergic inhibitory synap-
tic transmission (Lauro et al., 2008; Lauro et al., 2010; Piccinin et al.,
2010; Scianni et al., 2013). In addition, in cortical brain tissues from
TLE patients, modulating this pathway by adding recombinant
fractalkine, decreased GABA current reduction on repeated GABA appli-
cation, though, the recovery of currents to basal valueswas also affected,
suggesting a possible desensitization of GABA receptors (Roseti et al.,
2013). However,we did notﬁnd changes in the synaptic protein expres-
sion at one week post-SE, with or without CX3CR1 antibody treatment.
Further studies are needed to evaluate whether more sub-regional
changes in network excitability may explain the neuroprotection in-
duced by the current anti-CX3CR1 treatment.
Given that neuroblast production is normally increased acutely fol-
lowing seizures and the survival is compromised by microglial activa-
tion (Ekdahl et al., 2003), the reduced neuroblast production one
week post-SE following CX3CR1 antibody treatment was unexpected.
However, since both the number of proliferating cells and neuroblasts
were reduced, it is likely that the CX3CR1 antibody treatment was
primarily affecting the proliferation phase. When the pathological envi-
ronment surrounding the neurogenic nichewas reduced due to CX3CR1
antibody treatment, this could have resulted in less proliferation.
Alternatively, the downstream effect of the CX3CR1 pathway on cell
proliferation could be independent of its role in microglial activation.
Partly supporting this later speculation is the fact that CX3CR1 receptor
knockout mice show a reduced basal neurogenesis without a change in
microglial cell numbers (Paolicelli et al., 2011; Vukovic et al., 2012;
Fumagalli et al., 2013). Furthermore, a recent study has shown that
CX3CR1 deﬁcient mice do not display increased neurogenesis despite
environmental enrichment (Reshef et al., 2014). However, young mice
treated with anti-CX3CR1 antibody during normal physiology show re-
duced neurogenesis along with increased microglial cell numbers
(Bachstetter et al., 2011). In our study, we also observed increased cell
proliferation in the SGZ following fractalkine treatment post-SE.
Because neuroblast production was not altered at this time point, it is
not clear what cell type the increased proliferation pool represents. It
may still result in neuroblast production at later timepoints and thereby
be consistent with the ﬁnding from Bachstetter et al. (2011). They
showed increased cell proliferation,without a change in neuroblast pro-
duction or microglial activation during normal physiological conditions
after one week of fractalkine treatment in aged rats, but an increase in
both proliferation and neuroblast production after 2 weeks of adminis-
tration. In summary, to further understand the diverse results presented
so far following CX3CR1 modulation, manipulation of single down-
stream pathways of the CX3CR1 may help in deﬁning its importance
for microglial activation and a dependent or independent role in cell
proliferation and neuroblast production.
Whether the fractalkine–CX3CR1 pathway is also modulating
later stages of neurogenesis, including differentiation and synaptic
integration, remains to be investigated. In addition, future studies
will show whether the alterations in seizure-induced pathology
following CX3CR1 antibody treatment during early periods of
epileptogenesis may eventually decrease the development of spon-
taneous seizures.Conclusions
This study shows an important role of the fractalkine–CX3CR1
signaling pathway in limbic seizure-induced hippocampal pathologies
including microglial activation, neurodegeneration and neuroblast pro-
duction. It also suggests that neuroblast production following seizures
may partly occur as a result of microglial activation.
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